EU Legal Opinion In Truvada Case Could Complicate SPC Grant Process
Executive Summary
In one of several cases under way regarding the criteria for awarding supplementary protection certificates, an advocate general of the Court of Justice of the EU has come up with some new legal tests that experts say could make it more difficult to obtain SPCs in certain circumstances.
You may also be interested in...
CJEU Ruling Could Prove Problematic For Gilead’s Truvada SPC
A ruling by the Court of Justice of the EU has attempted to clarify the situation regarding the conditions for a supplementary protection certificate, but while it may help to settle the UK case regarding Gilead’s combination HIV drug Truvada, one practitioner says the case raises more questions than it answers.
CJEU Ruling Could Prove Problematic For Gilead’s Truvada SPC
A ruling by the Court of Justice of the EU has attempted to clarify the situation regarding the conditions for a supplementary protection certificate, but while it may help to settle the UK case regarding Gilead’s combination HIV drug Truvada, one practitioner says the case raises more questions than it answers.
Consultation To Help Determine Whether EU SPC Framework Fit For Purpose
The European Commission has launched a consultation on proposals to “recalibrate” supplementary protection certificates and patent research exemptions.